Merck's Keytruda demonstrated a statistically significant 23% reduction in the risk of melanoma recurrence compared to Ipilimumab in a Phase 3 trial.
A Turning Point in Adjuvant Immunotherapy
Melanoma is a deadly skin cancer with a high risk of recurrence even after surgery. Previously, high-risk Stage III-IV patients who underwent surgery received adjuvant therapy with high-dose interferon alfa-2b (Intron A) from Merck & Co. (MRK) or CTLA-4 inhibitor Ipilimumab (Yervoy) from Bristol Myers Squibb (BMY). However, these existing treatments had limitations due to high systemic toxicity and severe side effects, making long-term maintenance difficult. At this point, the emergence of anti-PD-1 immune checkpoint inhibitor Pembrolizumab (Keytruda) began to drive efforts to reduce side effects and improve recurrence rates.
Key Design and Results of the SWOG S1404 Trial
The SWOG S1404 clinical trial was a Phase 3 randomized controlled study that directly compared the efficacy of Pembrolizumab with the existing standard of care in high-risk Stage III-IV melanoma patients after surgery. Patients received either Pembrolizumab 200mg or high-dose interferon or Ipilimumab. With a median follow-up of 47.5 months, the Pembrolizumab group showed a statistically significant improvement in recurrence-free survival (RFS) compared to the control group. The hazard ratio (HR) for RFS was 0.77 (99.62% CI, 0.59-0.99, p=0.002), quantitatively demonstrating a 23% reduction in the risk of recurrence.
Limitations in Overall Survival and Clinical Significance
However, in this trial, the hazard ratio for overall survival (OS) was 0.837 (96.3% CI, 0.622-1.297, p=0.15), which did not reach statistical significance. Experts analyze that the difference in OS was diluted by the crossover effect, where control group patients who relapsed received effective subsequent immunotherapy such as Keytruda. Although it failed to demonstrate an improvement in OS, Pembrolizumab showed superior tolerability in terms of quality of life (QoL), significantly reducing the incidence of grade 3 or higher severe adverse events. This provides a practical benefit by helping high-risk patients maintain their daily lives during a long treatment period.
Market Share in Melanoma and Financial Impact
Keytruda has already established a dominant position in the market by receiving FDA approval in February 2019 as an adjuvant therapy for Stage III melanoma. The release of these final Phase 3 results will further solidify Keytruda's prescription credibility and limit the market share of competing products such as BMS's Yervoy. The global melanoma treatment market is expected to reach approximately USD 11.25 billion by 2026, and Keytruda's position in this market will become even stronger. Merck's annual revenue exceeded USD 31.7 billion in 2025, and the company is strengthening its defensive strategies, such as developing subcutaneous formulations, to address the patent cliff in 2028.
This Phase 3 clinical trial demonstrated that Pembrolizumab significantly reduced the risk of recurrence-free survival (RFS) in high-risk melanoma patients, with a hazard ratio of 0.77, further solidifying its position as a standard adjuvant therapy. For clinicians, it provides superior safety and quality of life data compared to existing standard treatments such as high-dose interferon and Ipilimumab, which had high toxicity, and serves as a basis for accelerating prescription changes in clinical practice. From an investor's perspective, it will be a short-term milestone in defending Merck & Co.'s market share in the global melanoma market, which is projected to reach approximately USD 11.25 billion by 2026, and in inducing a decline in the sales of Bristol Myers Squibb's Ipilimumab. In the medium to long term, it is expected to provide researchers with a new framework for verifying pure survival benefits in future subsequent clinical trials by analyzing the factors that caused the failure to achieve statistical improvement in overall survival (OS), such as the crossover effect.
Source: ClinicalTrials.gov (api_ct)